Article
Pharmacology & Pharmacy
Guang Yang, Sonal Singh, Caitrin W. McDonough, Jatinder K. Lamba, Issam Hamadeh, L. Shannon Holliday, Danxin Wang, Joseph Katz, Peter A. Lakatos, Bernadett Balla, Janos P. Kosa, Gian Andrea Pelliccioni, Douglas K. Price, Sara L. Van Driest, William D. Figg, Taimour Langaee, Jan S. Moreb, Yan Gong
Summary: The study identified a lead SNP, rs2736308 on chromosome 8, associated with an increased risk of MRONJ in patients with cancer and osteoporosis. This SNP is linked to genes regulating bone mineral density, providing insights into the potential mechanism of MRONJ.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Medicine, General & Internal
George Adrian Ciobanu, Adrian Camen, Mihaela Ionescu, Daniel Vlad, Cristina Maria Munteanu, Mircea Ionut Gheorghita, Cristian Virgil Lungulescu, Ionela Elisabeta Staicu, Elena Claudia Sin, Luminita Chivu, Razvan Mercut, Sanda Mihaela Popescu
Summary: This study aimed to establish the importance of risk factors in the development of MRONJ in cancer patients receiving zoledronic acid therapy. The analysis of 174 cancer patients revealed that treatment duration, chemotherapy, and hypertension were risk factors, while endocrine therapy and obesity were protective factors for MRONJ.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Endocrinology & Metabolism
L. dos Santos Ferreira, L. G. Abreu, C. B. Calderipe, M. D. Martins, L. F. Schuch, A. C. U. Vasconcelos
Summary: The study aimed to integrate data on the use of TPTD for MRONJ cases, finding that TPTD in combination with another therapy, especially antibiotic therapy, can be considered an effective protocol for MRONJ.
OSTEOPOROSIS INTERNATIONAL
(2021)
Article
Medicine, General & Internal
Yesel Kim, Jeong-Kui Ku
Summary: This study successfully established a MRONJ rat model on the calvaria, which mimicked the characteristics of MRONJ and can be used for developing treatments for MRONJ.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cell Biology
Xin Chen, Weiwen Zhu, Rongyao Xu, Xin Shen, Yu Fu, Jie Cheng, Laikui Liu, Hongbing Jiang
Summary: This study revealed that long-term use of bisphosphonates such as Zoledronic Acid (ZA) may lead to Bisphosphonate-related Osteonecrosis of the Jaw (BRONJ) by inhibiting macrophage efferocytosis and promoting osteocytic apoptosis. Additionally, supplementing with geranylgeraniol (GGOH) can restore Rac1 homeostasis and rescue macrophage efferocytosis, potentially providing a new treatment approach for BRONJ.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Multidisciplinary Sciences
Takuma Watanabe, Keita Asai, Shizuko Fukuhara, Ryuji Uozumi, Kazuhisa Bessho
Summary: This study evaluated the variables associated with treatment outcomes in patients with ARONJ at a single center, finding that surgery and HBO therapy were effective treatment approaches for both stage 2 and 3 ARONJ. Extensive surgery was more effective in healing than conservative surgery for stage 2 ARONJ, while >= 46 sessions of HBO therapy was less associated with healing in the same stage.
Article
Multidisciplinary Sciences
Kyeong-Mee Park, Namkwon Lee, Jaeyeon Kim, Hyun Sil Kim, Wonse Park
Summary: This study aimed to investigate the preventive effect of teriparatide (TPD) administration on medication-related osteonecrosis of the jaw (MRONJ) before tooth extraction. The results showed that TPD reduced the occurrence of MRONJ in rats treated with zoledronic acid.
SCIENTIFIC REPORTS
(2023)
Article
Multidisciplinary Sciences
Kota Morishita, Sakiko Soutome, Mitsunobu Otsuru, Saki Hayashida, Maho Murata, Miho Sasaki, Yukinori Takagi, Misa Sumi, Masahiro Umeda
Summary: The study found that a drug holiday of 3 months for medication-related osteonecrosis of the jaw in osteoporosis patients receiving antiresorptive agents does not promote sequestra separation or improve treatment outcomes, and early surgical therapy is recommended.
SCIENTIFIC REPORTS
(2022)
Article
Dentistry, Oral Surgery & Medicine
Koma Sanda, Yasunori Ayukawa, Noriyuki Yasunami, Naomi Adachi, Akihiro Furuhashi, Mikio Imai, Ken Matsunaka, Kiyoshi Koyano
Summary: The study found that injecting fluvastatin after tooth extraction can promote the healing of medication-related osteonecrosis of the jaw-like lesions, reducing the risk of necrotic bone formation.
JOURNAL OF PERIODONTOLOGY
(2022)
Review
Dentistry, Oral Surgery & Medicine
Ole Kristian Lobekk, Ward Dijkstra, Torbjorn O. Pedersen
Summary: The study compared the outcomes of surgical and conservative treatment for medication-related osteonecrosis of the jaw, with slightly better results reported after surgical treatment. However, there are issues with poor quality of evidence and high risk of bias in the research.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY
(2021)
Article
Chemistry, Medicinal
Jung Sun Kim, Jin Woo Kim, Jeong Yee, Sun Jong Kim, Jee Eun Chung, Hye Sun Gwak
Summary: This study aimed to investigate the relationship between PPARγ and PPARGC1A polymorphisms and the development of BRONJ in female osteoporosis patients undergoing bisphosphonate treatment. The results showed that PPARGC1A rs2946385 and rs10020457 polymorphisms were significantly associated with BRONJ. Patients with the combined genotypes of GG in both PPARγ rs1151999 and PPARGC1A rs2946385 had a higher risk of BRONJ. Old age (≥70 years) and long duration of bisphosphonate use (≥60 months) also increased the risk of BRONJ.
Article
Dentistry, Oral Surgery & Medicine
C. G. J. Monteiro, E. M. Vieira, C. Emerick, R. S. Azevedo, V. A. B. Pascoal, N. Homsi, R. X. Lins
Summary: The study aimed to evaluate the preventive effect of ozonated oil on the development of MRONJ-like lesions at tooth extraction sites in rats receiving zoledronic acid treatment. While there was no statistically significant difference in the average area of vital and necrotic bone between the groups, ozonated oil appeared to reduce osteonecrosis development. Further research is needed to confirm these findings.
CLINICAL ORAL INVESTIGATIONS
(2021)
Article
Biology
Hiroko Okawa, Takeru Kondo, Akishige Hokugo, Philip Cherian, Jesus J. Campagna, Nicholas A. Lentini, Eric C. Sung, Samantha Chiang, Yi-Ling Lin, Frank H. Ebetino, Varghese John, Shuting Sun, Charles E. McKenna, Ichiro Nishimura
Summary: This study presents a novel method to elucidate the pathological mechanism of BRONJ and demonstrates the potential of HMDP-DNV as an effective therapy. The results show that the intra-oral application of HMDP-DNV can selectively remove legacy N-BP from the jawbone and accelerate wound healing and bone socket healing, while attenuating osteonecrosis development. Single cell RNA sequencing reveals the resolution of chronic inflammation by increasing the expression of anti-inflammatory signature genes. This research suggests that BRONJ pathology is related to N-BP levels in jawbones.
Article
Chemistry, Medicinal
Ken Matsunaka, Mikio Imai, Koma Sanda, Noriyuki Yasunami, Akihiro Furuhashi, Ikiru Atsuta, Hiroko Wada, Yasunori Ayukawa
Summary: This study found that a single injection of benidipine near MRONJ-like lesions can promote healing of osteonecrotic extraction socket, reducing the area of necrotic bone and recovering soft tissue continuity.
Article
Dentistry, Oral Surgery & Medicine
Min-Jeong Kwoen, Jung-Hyun Park, Keun-Suh Kim, Jae-Ryun Lee, Jin-Woo Kim, HyeJin Lee, Hyo-Jung Lee
Summary: The presence of periodontal disease significantly increases the risk of medication-related osteonecrosis of the jaw (MRONJ) in patients, even without tooth extraction. Therefore, patients taking bisphosphonates should actively manage and treat periodontal diseases.
JOURNAL OF PERIODONTOLOGY
(2023)